COVID-19 Vaccination Coverage Among Adolescents Aged 12–17 Years — U.S. December 14, 2020–July 31, 2021

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Murthy, Bhavini Patel ; Zell, Elizabeth ; Saelee, Ryan ; Murthy, Neil ; Meng, Lu ; Meador, Seth ; Reed, Kirsten ; Shaw, Lauren ; Gibbs-Scharf, Lynn ; McNaghten, A.D. ; Patel, Anita ; Stokley, Shannon ; Flores, Stephen ; Yoder, Jonathan S. ; Black, Carla L. ; Harris, LaTreace Q.
• Description:
  Although severe COVID-19 illness and hospitalization are more common among adults, these outcomes can occur in adolescents (1). Nearly one third of adolescents aged 12-17 years hospitalized with COVID-19 during March 2020-April 2021 required intensive care, and 5% of those hospitalized required endotracheal intubation and mechanical ventilation (2). On December 11, 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine for adolescents aged 16-17 years; on May 10, 2021, the EUA was expanded to include adolescents aged 12-15 years; and on August 23, 2021, FDA granted approval of the vaccine for persons aged ≥16 years. To assess progress in adolescent COVID-19 vaccination in the U.S. CDC assessed coverage with ≥1 dose* and completion of the 2-dose vaccination series| among adolescents aged 12-17 years using vaccine administration data for 49 U.S. states (all except Idaho) and the District of Columbia (DC) during December 14, 2020-July 31, 2021. As of July 31, 2021, COVID-19 vaccination coverage among U.S. adolescents aged 12-17 years was 42.4% for ≥1 dose and 31.9% for series completion. Vaccination coverage with ≥1 dose varied by state (range = 20.2% [Mississippi] to 70.1% [Vermont]) and for series completion (range = 10.7% [Mississippi] to 60.3% [Vermont]). By age group, 36.0%, 40.9%, and 50.6% of adolescents aged 12-13, 14-15, and 16-17 years, respectively, received ≥1 dose; 25.4%, 30.5%, and 40.3%, respectively, completed the vaccine series. Improving vaccination coverage and implementing COVID-19 Prevention strategies are crucial to reduce COVID-19-associated morbidity and Mortality among adolescents and to facilitate safer reopening of schools for in-person learning.
• Subjects:
  Adolescent Child CoronaVirus Infections COVID-19 COVID-19 Vaccines Female Humans Male Vaccination Coverage
• Source:
  MMWR Morbidity Mortal Weekly Rep. 70(35):1206-1213
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/MMWRmm7035e1
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  34473680
• Pubmed Central ID:
  PMC8422871
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  8 pdf pages
• Volume:
  70
• Issue:
  35
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:359b5fc4139abebfecb0fff2c618c8343fa6277cdb5f4e18a7e3d304be0d3ce5aaefd2d45480d41ea8b7691e5b03544b05f1f59ea8108d28c5bcdf578519a522
• Download URL:
  https://stacks.cdc.gov/view/cdc/110233/cdc_110233_DS1.pdf
• File Type:
  [PDF - 248.50 KB ]